

#3/le #
may
4/2/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Stephen J. GARGER, et al.

Group Art Unit: 1656-38
Examiner: Not Yet AssignedAttorney's Docket No:
00801.0087.CPUS07

Application Serial No. 09/993,059

Filed: November 13, 2001

For: **PRODUCTION OF
LYSOSOMAL ENZYMES IN
PLANTS BY TRANSIENT
EXPRESSION**RECEIVED
MAR 28 2002
TECH CENTER 1600/2900PRELIMINARY AMENDMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

AMENDMENTClean Version of the Amended Specification and ClaimsIn the Specification:

The paragraph beginning at page 24, line 9 should read:

a1

"Gal-A is one of many proteins that require glycan site occupancy at N-linked sites to achieve proper folding and stability. The ability to successfully target the enzyme in Fabry patients is also likely to be glycosylation-dependent. This requirement presently limits the expression possibilities to eukaryotic cell types. Recombinant proteins synthesized in baculovirus and yeast expression systems are often hyperglycosylated and highly heterogeneous complicating the preparation of therapeutically effective glycoforms from these sources. The rGal-A synthesized in plants is a relatively homogeneous glycoform as analyzed by its SDS-PAGE electrophoretic mobility and comigrates with rGal-A produced purified from placenta (Fig. 3). The expression results (yield and purity) we have already presented are unprecedented in any eukaryote system for a glycosylated enzyme and are not likely to be achieved in the

03/26/2002 HUONG1 00000061 09993059

01 FC:203
02 FC:202252.00 OP
42.00 OP